Japan, Oct. 23 -- GENMAB AS has got intellectual property rights for 'AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT.' Other related details are as follows:
Application Number: JP,2024-009200
Category (FI): A61K31/155,A61K31/282,A61K31/337,A61K31/4188,A61K31/437,A61K31/475,A61K31/506,A61K31/517,A61K31/704,A61K31/7048,A61K33/243,A61K38/07,A61K39/395@E,A61K39/395@T,A61K45/00,A61K47/68,A61P15/00,A61P35/00,A61P35/02,A61P43/00,111,A61P43/00,121,C07K16/28,C12N15/13
Stage: Grant (IP right granted following substantive examination.)
Filing Date: Jan. 25, 2024
Publication Date: March 19, 2024
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication.
